HeartBeam : Investor Presentation – April 2026
BEAT
Published on 04/16/2026 at 04:40 pm EDT
Total Heart Intelligence…
Wherever You Are
ADVANCED CARDIAC INTELLIGENCE PLATFORM | 25 PATENTS | FDA CLEARED* INVESTOR PRESENTATION April 2026
*FDA cleared for arrhythmia assessment only. NASDAQ: BEAT
THE GAP IN CARDIAC DETECTION
Heart attack detection requires 12-Lead ECG data, which is primarily available
in clinical settings.
Consumer and wearable ECG devices do not provide sufficient spatial orientation for ischemia detection. As a result, clinicians lack reliable data when symptoms occur outside the hospital.
Investor Presentation 2026 3
Ischemia product not cleared by FDA and not available for sale in the United States or other geographies.
Patient Delay is the Major Driver Behind the #1 Cause of Death
Treatment time in hospital is optimized. Patient delay happens before arrival.
Patients Delay 3+ Hours Before Taking Action
Uncertainty Delays Action
Treatment Time is Optimized Once the Patient Reaches the Hospital
Optimized, in guidelines
Rapid 12-Lead ECG in guidelines
PATIENT OUTCOME
Every 30 Minute
Delay Increases:
8.7%
Heart failure risk
7.5%
1-year mortality
COSTLY
COMPLICATIONS
Heart failure
drives:
$30,000
annual cost
per patient
5-year avg.
life expectancy
Heart Failure costs:
• $30,000 annual cost per patient
• 5-year avg. life expectancy
Rapid EMS activation and transport
Streamlined emergency room triage
Immediate stenting with door-to-balloon time under 90 minutes
There is no dependable solution to reduce this pre-hospital delay.
Current at-home ECG tools cannot reliably detect heart attacks.
Investor Presentation 2026 4
De Luca G. Circulation. 2004 Mar 16;109(10):1223-5 Heidenreich PA, J Card Fail. 2022 Mar;28(3):453-466. Heart Failure Society of American, Heart Failure Facts & Information. Data shown reflects the burden of heart attack, not general cardiovascular disease Ischemia product not cleared by FDA and not available for sale in the United States or other geographies.
Consumer ECGs Have Limited Capabilities & Traditional ECGs are Limited to Healthcare Facilities
Noisy signals
Limited diagnostic capabilities False positives
Bulky equipment and wires Requires trained operators Only in hospitals or ERs
Patient immobilized during testing
Not available when symptoms strike
Investor Presentation 2026 5
5
Ischemia product not cleared by FDA and not available for sale in the United States or other geographies.
HeartBeam Brings a Clinical-Grade 12-Lead ECG Into the Home
Investor Presentation 2026 6
BRINGING CARE BEYOND THE HOSPITAL
HeartBeam is the first ever cable-free, synthesized, 12-Lead ECG platform for arrhythmia assessment, delivering clinical-grade insights in real time, wherever symptoms occur.
Investor Presentation 2026 7
FDA cleared for arrhythmia assessment. Ischemia and AI algorithm products are not cleared by FDA and not available for sale in the United States or other geographies.
the Heartbeam
Click here to watch the demo video
Heart Beam
Investor Presentation 2026 8
FDA cleared for arrhythmia assessment. Ischemia and AI algorithm products are not cleared by FDA and not available for sale in the United States or other geographies.
This Platform Addresses Tens of Millions of Patients Across Multiple Segments
Investor Presentation 2026 9
CORE PLATFORM
FORM FACTORS
HEARTBEAM SYSTEM*
PATENTED 3D SIGNAL
COLLECTION TECHNOLOGY
ON-DEMAND 12-LEAD PATCH
CONTINUOUS
CABLE-FREE 12-LEAD ECG FOR AT-HOME USE
1-LEAD → 12-LEAD
ON DEMAND
APPLICATIONS ENABLED
Investor Presentation 2026
*FDA cleared for arrhythmia assessment. Ischemia, AI algorithm and 12-lead patch products are not
cleared by FDA and not available for sale in the United States or other geographies.
ARRHYTHMIA HEART ATTACK DETECTION
PERSONALIZED AI ALGORITHMS
10
Fundamental Advances Covered by 25 Patents
Enables HeartBeam's Unique Approach
Capturing the Heart's Signals
in 3 Dimensions
Patented method that collects heart signals in three non-coplanar dimensions, capturing the full electrical activity of the heart.
Novel Form Factor
Proprietary resistive network enables a three-dimensional approach and a synthesized 12-Lead ECG, all in a credit card-sized device.
Clinically Accurate Conversion
Personalized algorithms convert signals from three non-coplanar dimensions into physician-ready 12-Lead ECG readouts in real time.
Investor Presentation 2026 11
50M+ Patient, $40B Cardiac Platform Opportunity
Scaling from direct-pay launch to large areas of clinical need
INITIAL MARKET ENTRY POINT
PATIENTS
Concierge
& Preventive Cardiology
EXPANSION OPPORTUNITY
PATIENTS
Broader
Patient Pay -Telehealth, Direct to Consumer
5M+
STRUCTURED
DIRECT-PAY HEALTHCARE
High touch membership-based health services
$4Bi
20M+
HEART ATTACK RISK
Adults in the U.S. at risk of Heart Attack
$15Bii
50M+
TOTAL AT-RISK PATIENTS
That could benefit from HeartBeam Platform offerings
$40Biii
DATA:
5.0+ million patients in Direct Patient Pay in U.S. (including 1.5M+ in Concierge Market and 3.5M+ in broader patient pay market) × $750 per year per patient
20+ million patients in U.S. at risk of heart attack (8 million prior MI + 12 million at high risk) × $750 per year per patient
Investor Presentation 2026
260+ million adults in U.S. × ~20% either rhythm diagnosis, palpitations, or recurring unexplained cardiac symptoms
reported at some point × $750 per year per patient; $750 per year per patient assumed as baseline until further validation of 12
market opportunity
The HeartBeam System is FDA Cleared
and Ready for Launch
Investor Presentation 2026 13
HeartBeam System Cleared and Ready For Launch
FDA 510(k) clearances for arrhythmia detection:
12/2024:
The HeartBeam System
12/2025:
12-Lead ECG synthesis algorithm
Strong IP:
25 Issued Patents Worldwide
Robust Clinical Evidence:
14 Clinical Papers & Presentations
Investor Presentation 2026 14
14
We Are Entering
This Market Strategically
Investor Presentation 2026 15
An Ideal Early Market: Concierge and Preventive Cardiology
Strong willingness to pay
Evidence of demand
80%
92%
1.5M+ Americans pay out of pocket for concierge medicine
Cardiovascular care becomes a major healthcare spending category beginning in midlife (ages 45-70), a core demographic for concierge medicine
Concierge and longevity programs cost an average of $3,000 to $10,000 per year with premium practices costing $50,000+
HeartBeam pricing at
$500 to $1,000 per year per patient is a small fraction of current spend
HIGH-NET-WORTH INDIVIDUALS
Likely
>2x
to purchase
HIGH-NET-WORTH INDIVIDUALS
Prefer premium
72%
over basic tier
Investor Presentation 2026
Targeting concierge and preventive cardiology enables premium pricing, controlled rollout, and early revenue generation
CONCIERGE PATIENTS
Willing to pay more than twice what non-concierge high net worth individuals would pay
CONCIERGE PHYSICIANS
Would recommend to their patients
16
Sources: Circulation. 2021 Apr 30;144(4):271-282. Circulation. 2024 Jul 23;150(4):e89-e101. https://www.aarp.org/health/conditions-treatments/what-to-know-about-concierge-medicine/ https://www.bostonglobe.com/2024/11/15/business/concierge-medicine-doctors-primary-care-yearly-membership-fee/
Source: Third-party market research conducted by HeartBeam in 2024 and 2025. N = 231 high net-worth users; N = 30 concierge and preventive cardiology physicians
Concierge and Preventive Cardiology:
Patients are demanding it.
Physicians want to offer it.
PATIENTS PHYSICIANS
Patients actively seek
advanced technology
Demand latest clinical innovations and technology
Proven willingness to pay
Tech-forward early adopters
Desire to differentiate their practice
Trust physician recommendations
HeartBeam provides the peace of mind of at-home 12-Lead ECG +
on-call cardiologists
Physician-endorsed recommendation
Enhance relationship with patients
HeartBeam offers 24/7 peace of mind for patients and promotes proactive care
An efficient sales process and rapid adoption: these practices work together with HeartBeam to sell to patients
Investor Presentation 2026 17
Foundation for Scale.
Proving success in Cardiology
and Executive Concierge Practices
IMMEDIATE FOCUS FOR LIMITED LAUNCH:
CARDIOLOGY AND EXECUTIVE CONCIERGE
Practice Size: 400-4,000 patients
Concentrated in NY, South Florida, Dallas, Southern California
Predominantly physician owned
10% of 1.5M Concierge Market
INITIAL MARKET ENTRY POINT:
Concierge and Preventive Cardiology
1.5M
PATIENTS
EXPANSION OPPORTUNITY
3.5M
PATIENTS
Creates a Playbook to Accelerate Growth Nationwide
ACCELERATING GROWTH: NATIONAL CHAINS
Practice Size: 8-10 chains account for
~750,000 patients
Leverage validated proof points from initial launch
Standardize workflow
and implementation at scale
Utilize high HSA and FSA adoption Cost-effective expansion strategy
doesn't require huge sales force
Potential to scale with distribution partner
Break-even achievable within this segment alone
EXPANSION OPPORTUNITY:
Broader Patient Pay - Direct Primary Care, Telehealth, Referrals to HeartBeam centers
Investor Presentation 2026 18
HeartBeam Product Offering: Annual Subscription to Patients
Equipment
Cable-free 12L ECG synthesized through 3D ECG technology
My HeartBeam patient app
FDA cleared for arrhythmia assessment only.
Services
Routine Recordings
Symptomatic
Unlimited Reads (Automated arrhythmia
assessment, est. end of 2026)
Credits for On-call cardiologist ECG interpretation in <30 min
Additional Tools
•
•
•
Sharable summary reports Community features* Wearable integration*
•
•
•
Telehealth consultations* AI wellness algorithms*
MD assessments of interval trends*
* Planned for first year post-launch
Commercial Launch is Only the Beginning
Investor Presentation 2026 20
Disclaimer
Heartbeam Inc. published this content on April 16, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 16, 2026 at 20:37 UTC.